Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension

Trial Profile

Long-term Single-arm Open-label Study, to Assess the Safety and Tolerability of ACT-293987 in Patients With Pulmonary Arterial Hypertension

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Selexipag (Primary)
  • Indications Pulmonary arterial hypertension
  • Focus Adverse reactions
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 29 Apr 2016 Planned End Date changed from 1 Feb 2018 to 1 Feb 2021.
    • 29 Apr 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Feb 2021.
    • 25 Sep 2014 Planned End Date changed from 1 Feb 2015 to 1 Feb 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top